Magna

Uhnder Inc. is a technology company focused on developing innovative products for sensing, cognition, and communication within the Internet of Things (IoT) market. Founded in 2015 and headquartered in California, with engineering and operations in Austin and St. Louis, Uhnder specializes in a digital automotive radar-on-chip. This technology offers a more accurate and reliable alternative to traditional light detection and ranging (lidar) systems, which are commonly used in autonomous vehicles. The radar-on-chip enhances safety by helping to avoid collisions, providing alerts for potential issues, and enabling quick localization through electronic navigation fences. By improving feedback response and system automation, Uhnder aims to transform the autonomous vehicle landscape.

Zubie is a connected vehicle services company focused on providing consumers and businesses relevant vehicle health, location, and safety information. With a simple plug-in of the Zubie key, users can easily monitor their vehicle data through its Zubie mobile apps for both iOS and Android. Learn more about our low-cost fleet management solution for businesses at http://zubie.com/fleet or our consumer offering at http://zubie.com. A Zubie subscription includes the Zubie Key (OBDII device), iOS/Android apps, and online web portal.

Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

Amedica is a spinal and orthopedic implant company specializing in the development of implants using silicon nitride ceramic technology. It focuses on creating innovative spinal and total joint implants, leveraging its expertise in the manufacturing and research of silicon nitride ceramics. The company operates an ISO 13485 certified manufacturing facility, where it produces spinal implants that are exclusively distributed through CTL-Amedica, its retail channel. Amedica aims to enhance patient outcomes by utilizing the unique properties of silicon nitride in its medical products.